Chronic graft-versus-host disease (cGVHD) is one of the major chronic complications of hematopoietic stem cell transplantation (HSCT) and occurs within the first years after transplantation. The close similarities between cGVHD and autoimmune diseases, such as systemic sclerosis or Sjögren's syndrome, were recognized early. 1 However, follow-up data of cGVHD in long-term transplanted patients are scarce and pathogenetic mechanisms are still poorly understood. These mechanisms have gained renewed interest at a time when HSCT is discussed as a therapeutic option for severe autoimmune disorders. 2 In addition, the occurrence of a syndrome smiliar to connective tissue diseases in long-term survivors which might not be related to cGVHD has been postulated. 3 There are several reports on various autoantibodies being detected after HSCT. [3] [4] [5] [6] The occurrence of these autoantibodies is independent of acute or chronic GVHD and their clinical significance is unknown.
In a retrospective study, we analyzed 38 patients, all long-term survivors of at least 10 years after HSCT from an HLA-identical sibling. Data were collected during annual routine follow-up of the patients. We screened for the occurrence of autoantibodies and a possible association with symptoms of a connective tissue disease.
The following autoantibodies were analyzed by standard assays: anti-nuclear, anti-mitochondrial, anti-parietal cell, anti-heart muscle, anti-smooth muscle, anti-skeletal muscle and anti-parotid antibodies. We specifically looked for symptoms which could be related to an underlying autoimmune disease: arthralgia/myalgia, sicca syndrome (dry eyes, dry mouth), skin efflorescences, reduced exercise tolerance (Karnofsky index Ͻ100%) and fatigue syndrome. Symptoms were added in a score from 0 to 5.
Statistical analyses were carried out by the Wilcoxon Mann-Whitney U test, Fisher's exact test and Spearman rank correlation coefficient.
Of the 38 patients analyzed (19 male, 19 female), 17 had acute myeloblastic leukemia, 10 chronic myeloblastic leukemia, five severe aplastic anemia, three acute lymphoblastic leukemia, two myelodysplastic syndrome and one non-Hodgkin's lymphoma.
Autoantibodies were found in 20 patients (group I), whereas 18 patients were repeatedly negative (group II). In group I, 17 patients had anti-nuclear, two had anti-mitochondrial, three anti-parietal and three anti-heart muscle antibodies. Both groups were statistically not different concerning age (group I: median 39.5 years, range 16-59 vs group II: median 39 years, range 21-56), sex, underlying disease, time after HSCT (14.1 vs 13.7 years), sex of the donor, T cell depletion of the graft, HLA antigens, seropositivity (IgG) for CMV (8/20 vs 7/18) or hepatitis C. However, all patients with severe aplastic anemia (n ϭ 5) were autoantibody positive.
The incidence and degree of cGVHD were not significantly different (12/20 vs 7/18), but the number of patients with ongoing immunosuppression for persistent cGVHD (5/20 vs 0/18; P Ͻ 0.05) was significant. The degree of a preceding cGVHD did not correlate with the level and/or number of the detected autoantibodies. The frequencies of restrictive pulmonary disease (3/20 vs 3/18) or elevated serum creatinine (2/20 vs 0/18) were the same in both groups. It is noteworthy that five autoantibody positive patients never had any signs of acute and/or chronic GVHD.
Autoantibody positive patients had significantly more symptoms than patients without autoantibodies (2.7 vs 1.44, P Ͻ 0.01). This difference remained significant when the five patients with ongoing immunosuppression for persistent cGVHD were excluded from the analysis (2.67 vs 1.44, P Ͻ 0.025). All scored symptoms were more frequently observed in autoantibody positive patients. The occurrence of sicca syndrome (16/20 vs 9/18; P Ͻ 0.05) and fatigue syndrome (7/20 vs 1/18; P Ͻ 0.05) was significantly more frequent. The percentage of autoantibody positive patients increased with the number of symptoms (Figure 1) .
It is possible that all signs and symptoms in these patients are the consequence of subclinical cGVHD. However, there are some arguments that a novel approach is needed to understand these phenomena. The majority of the autoantibody positive patients described here did not suffer from symptoms corresponding to classical cGVHD. The degree of a preceding cGVHD correlated neither with the level and/or number of detected autoantibodies nor with the scored symptoms presented at the time point of this analy- No. of second symptoms sis. There were several autoantibody positive patients who had never had acute or chronic GVHD. Furthermore, in a large study on long-term transplanted patients, 36% had a Karnofsky index Ͻ100% but only a few of them had active cGVHD. 7 This fits with earlier reports that the occurrence of autoantibodies after HSCT does not correlate with cGVHD but might be rather the expression of an abnormal B cell and/or T cell reconstitution. [3] [4] [5] [8] [9] [10] Therefore, we hypothesize that long-term survivors after allogeneic HSCT are at risk for a skewed immune reconstitution with altered immune response leading to late secondary 'auto'-immune like phenomena. More detailed and longer analyses are needed to confirm our observation. [1] [2] [3] Polyethyloxylated castor oil (PEO-CO) is a pharmaceutical vehicle marketed as Cremophor EL by BASF (Ludwigshafen, Germany). There are little experimental data, but the reactions have been classified as anaphylactoid. 4 We report the first case of a patient with anaphylactoid reactions to two drugs containing PEO-CO and the first case of an anaphylactoid reaction to subcutaneous phytonadione.
A 40-year-old female with a diagnosis of acute myelogenous leukemia (AML-M4) was admitted to hospital for matched related allogeneic peripheral blood stem cell transplantation. Allergic history was significant for urticaria following oral erythromycin. There was no personal history of asthma, anaphylaxis or allergic rhinitis. She had never previously been treated with phytonadione, cyclosporine or other medications containing PEO-CO.
One day prior to the stem cell transplant, i.v. cyclospor-ine, 158 mg (2.5 mg/kg per standard protocol for graft-versus-host disease prophylaxis (GVHD)) in 50 ml of 5% dextrose in water was started, to be given over 4 h. After infusion of 2 ml, the patient complained of flushing, nausea and urinary/fecal incontinence. On examination, vital signs were heart rate 100, blood pressure 240/120 and respiratory rate 22. Diphenhydramine, 50 mg i.v. was administered and the symptoms completely resolved. Cyclosporine was discontinued and i.v. tacrolimus was begun for GVHD prophylaxis. However, tacrolimus had to be stopped after 3 weeks due renal toxicity. At that time she was cautiously restarted on oral cyclosporine (non PEO-containing), which she tolerated well. On hospital day 16, the patient developed gastrointestinal bleeding. International normalized ratio (INR) was 9.6. Phytonadione (AquaMEPHYTON Merck, West Point, PA, USA), 10 mg was administered subcutaneously. Immediately after injection, the patient complained of dyspnea. On physical examination, vital signs were heart rate 155, blood pressure 160/135, and respiratory rate 33. Flushing and wheezing were present. The patient was treated with nebulized albuterol and ipratropium, 100 mg i.v. methylprednisolone and 50 mg i.v. diphenhydramine. The patient's symptoms resolved over several minutes. The patient later tolerated oral phytonadione (non-PEO-containing) well.
